Pages

Showing posts with label Serum Institute of India. Show all posts
Showing posts with label Serum Institute of India. Show all posts

Tuesday, 22 June 2021

14 Jun 21 Novavax vaccine shows 90% efficacy

Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply

A participant in Plano, Texas, is injected during Novavax’s North American COVID-19 vaccine trial this spring. The company reported its results today.

 
NOVAVAX


The dark horse vaccine company Novavax announced strong results today from a pivotal, 30,000-person trial of its pandemic coronavirus vaccine in the United States and Mexico. The vaccine uses a protein of SARS-CoV-2, a different technology from the COVID-19 vaccines authorized so far, and delivered 90.4% overall efficacy against symptomatic COVID-19 infections, and 100% protection against moderate and severe disease. Against eight viral variants of interest and concern, its efficacy was 93.2%. And the vaccine appeared safe and well-tolerated.

“This vaccine looks phenomenal. I am thrilled about these results,” says Monica Gandhi, an infectious disease physician and epidemiologist at the University of California, San Francisco. She notes that the clinical trial was highly diverse, with 44% nonwhite participants, and that the vaccine’s straightforward storage requirements could speed access to it in remote communities around the globe.

The difference of a few percentage points between Novavax’s 90% efficacy and the 95% and 94% efficacy of the Pfizer-BioNTech and Moderna vaccines is explained in part by Novavax’s later trial, which pitted the vaccine against viral variants, says John Moore, an immunologist at Weill Cornell Medicine and a participant in the Novavax trial. The trials of those other companies’ vaccines, composed of messenger RNA (mRNA), were completed before such variants were widely circulating.

“This is a vaccine whose efficacy is at least on a par with Pfizer and Moderna,” Moore says. “It’s essentially 100% protective against disease.”

One expert is less impressed, however. “The data they have [are] nothing spectacular,” says Vijay Samant, CEO of Xiconic Pharmaceuticals and former chief operating officer of Merck’s vaccine division. “The efficacy overall is couple of notches below the Pfizer and Moderna studies. … It’s a me-too vaccine at best.”

Novavax plans to apply to the U.S. Food and Drug Administration and other regulators for an emergency use authorization in the third quarter, once the company completes regulatory requirements aimed at ensuring its product consistently matches the vaccine used in the clinical trials, said President and CEO Stanley Erck.

Today’s announcement marks the end of a very long beginning for the once-moribund Gaithersburg, Maryland, company, which began to develop a vaccine in January 2020 and that July won $1.6 billion from the U.S. government’s Operation Warp Speed. But the company encountered production problems that delayed the launch of its North American clinical trial until late December 2020.

In the trial, two-thirds of participants at 113 sites in the United States and six sites in Mexico initially received two doses of the vaccine separated by 21 days. One-third of participants received a placebo. Between 25 January and 30 April, participants experienced 77 cases of COVID-19, 63 of them in the placebo group. All 14 cases in vaccinated participants were mild.

These results are similar to those Novavax reported in January from a late-stage trial of more than 15,000 people in the United Kingdom. That trial showed the vaccine efficacy was 89% overall, 86% against the Alpha variant that was first identified in the United Kingdom, and 96% against the original virus strain. But in a separate trial involving 4400 participants in South Africa, where the worrisome Beta variant arose and was circulating widely, the vaccine’s overall efficacy sank to 49%.

In the new trial, Novavax sequenced 70% of all the coronaviruses that caused illness. In more than half of the sequenced cases, they found the culprit was the Alpha variant, which accounted for 70% of U.S. infections by late April. But the company did not provide specific efficacy data against Alpha or any other variant. (Only two cases of the Beta variant were reported in the trial.)

“It doesn’t really address the lingering questions about how well the vaccine would work against ‘escape’ variants” such as Beta, says Natalie Dean, a biostatistician at the University of Florida.

The COVID-19 vaccines so far authorized by major Western regulatory agencies deliver genetic material that directs a recipient’s cells to make spike, a surface protein from SARS-CoV-2, that then trains the immune system to respond to the virus. Novavax’s vaccine instead delivers the spike protein itself, carried on soaplike particles and given extra punch by an immune-boosting substance called an adjuvant. Protein technology has been used for decades in vaccines against diseases including hepatitis B.

In clinical trials so far, Novavax’s vaccine has produced somewhat fewer powerful, though transient systemwide side effects such as headache, muscle pain, and fatigue, which many recipients of the Pfizer-BioNTech and Moderna vaccines experienced. For instance, 54% of participants who received Moderna’s vaccine as part of a 30,000-person trial reported at least one such effect; in Novavax’s 15,000-person trial in the United Kingdom, that number was 38%.

After a second dose of vaccine in the North American Novavax trial, about 40% of participants who received the active vaccine reported experiencing some degree of headache, muscle pain, or fatigue. But serious reactions were rare.

Having relatively mild side effects is a plus, says Mayank Mamtani, a biotechnology analyst who follows Novavax for B. Riley Securities. “This Novavax vaccine is going to be less reactogenic. You don’t have to cancel all your meetings” afterward, he says. He adds that the Novavax jab may find a niche as a booster vaccine in the United States, where he says such boosters may be needed by October or November. “We in this country love choice,” he adds.

Under its 2020 contract with Operation Warp Speed, Novavax committed to deliver 110 million doses to the U.S. government, although the country does not need them for initial vaccinations. Novavax expects to reach manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the fourth quarter of this year, Erck said.

The company has advance-purchase orders for about 200 million doses from another five Western governments and last month signed a deal to supply Gavi, the Vaccine Alliance, with 350 million doses for the COVID-19 Vaccines Global Access (COVAX) Facility, a global vaccine-sharing partnership. The Serum Institute of India, which is also making the Novavax vaccine, is slated to deliver another 750 million doses to COVAX, Novavax says. Serum plans to start delivering the Novavax vaccine by September, provided regulatory agencies have authorized it, officials there told Science.

Novavax’s production projections are substantially dialed back from earlier company predictions that it would ship 2 billion doses this year. That reflects the company’s struggle to scale up its manufacturing both at its own facilities and those of contractors and partner companies in 11 nations. “Novavax has been particularly challenged with executing on production scale-up efforts and manufacturing,” Mamtani wrote in a note to investment clients last month.

Unlike mRNA vaccines, which need to be stored frozen, Novavax’s protein vaccine can be stored in a refrigerator for up to 6 months, and, once removed, remains viable for 24 hours. Novavax has created a new version of its vaccine, adapted to the Beta variant, that could be used as a 1-year booster, the company says. On Friday, it announced positive results for the adapted vaccine in mice and baboons. Novavax says it is also working to customize its vaccine to other SARS-CoV-2 variants.

But Samant cautions that Novavax’s manufacturing struggles and the entrenched advantages of companies whose vaccines were approved months ago may make the small company’s climb to market share and profitability a tough one.

https://www.sciencemag.org/news/2021/06/powerful-new-covid-19-vaccine-shows-90-efficacy-could-boost-worlds-supply

Tuesday, 15 June 2021

India is at the centre of global shortage

India’s Serum Institute, the world’s biggest Covid-19 vaccine manufacturer, is at the centre of global shortage

The company has been unable to send any shots overseas since April, when the Indian government banned Covid-19 vaccine exports
Several nations, including Nepal, entered into direct contracts with Serum and are now racing to find new suppliers

BLOOMBERG
9 June 2021

The Indian company has been dogged by setbacks, from a ban on exports to a factory fire, that have hampered its ability to fill orders. Photo: Reuters
The Indian company has been dogged by setbacks, from a ban on exports to a factory fire, that have hampered its ability to fill orders. Photo: Reuters

Around the world, from Bangladesh to Nepal to Rwanda, vulnerable hotspots have been grappling with stalled Covid-19 vaccination programmes as they run out of doses. Many of those shortages can be traced back to a single company: the Serum Institute of India.

The world’s largest vaccine maker, Serum was last year named a top supplier of Covid-19 shots to Covax, the World Health Organization-backed initiative aimed at securing an equitable global roll-out. But the Indian company has been dogged by setbacks, from a ban on exports to a factory fire, that have hampered its ability to fill orders.

Covax has pledged to send shots to some 92 countries, but has so far received only 30 million of the minimum 200 million doses it ordered from Serum, which was to provide the bulk of its early supply. Serum’s travails have now become a key illustration of how the effort to inoculate against Covid-19 has failed the developing world, and a cautionary tale for becoming overreliant on one manufacturer amid a global crisis.

The shortages have occurred as the WHO and public health experts warn that low levels of vaccination in poorer nations could fuel the emergence of dangerous variants and lengthen the global pandemic. Other manufacturers have also had trouble meeting targets or ramping up production of Covid-19 shots, yet Serum’s shortfalls are particularly consequential because Covax and emerging countries were counting on it so heavily.

The company has been unable to send any shots overseas since April, when the Indian government banned Covid-19 vaccine exports amid the country’s devastating second wave. But some of Serum’s problems began long before.

Last year, Serum’s chief executive officer, Adar Poonawalla, pledged that his vaccine producing colossus would churn out 400 million doses of AstraZeneca’s coronavirus shot for low and middle-income countries by the end of 2020. A month into 2021, he said it had manufactured only 70 million shots because the company had been uncertain about when it would receive a license from India and didn’t have enough warehouse space.

Several nations also entered into direct contracts with Serum and are now racing to find new suppliers. In Nepal – which is struggling with a severe outbreak that’s even reached base camp of Mount Everest – the government says it’s received only half the 2 million shots it ordered directly from Serum, based in the city of Pune in neighbouring India. The rest were supposed to arrive by March.

“We are struggling with the shortage of vaccines,” said Tara Nath Pokhrel, the director of the family welfare division at Nepal’s health ministry.

Nepal, with a population of 28 million, says it’s received only 2.38 million doses: 1 million directly from Serum, another 1 million in grant aid from India, and the rest from Covax. Nepal had been expecting 13 million doses altogether from Covax. But those flows have dried up given Covax was relying heavily on Serum for supply and the Indian company is no longer exporting because of the government restrictions.

The decision to choose Serum as a major Covax supplier “was based, largely, on the company’s massive production capacity, ability to deliver at low cost and the fact that its vaccine was one of the earliest to gain WHO emergency use listing”, said Seth Berkley, chief executive officer at Gavi, the Vaccine Alliance, which has been facilitating Covax and helping fund its orders.

Berkley says Serum’s manufacturing capacity is now expanding, which will help India. Still, Covax and many developing countries are scrambling to find new sources of vaccines after Serum said in recent weeks that exports are unlikely to resume until the end of 2021 given the needs of its overwhelmed homeland.

It’s a void that could potentially be filled by Chinese vaccine makers, with shots from Sinovac Biotech and Sinopharm both recently approved for wider global use by the WHO. Bangladesh stopped giving out first vaccination doses after Serum’s supply shortages and then went on to halt its entire campaign. After the arrival of a limited supply of Chinese vaccines from Sinopharm, the South Asian country resumed inoculations for frontline and emergency workers, but is yet to start a mass vaccination programme.

The situation Serum now finds itself in is a turnaround from a year ago. Then, its owners – the billionaire Poonawalla family, which founded the firm in 1966 to diversify their business away from racehorse breeding – were thrust into the global spotlight after agreeing to mass produce AstraZeneca’s vaccine, which is called Covishield in India.

Serum had long been a supplier of measles and polio inoculations to the developing world and Adar Poonawalla, who became CEO in 2011, revelled in its position at the centre of the historic Covid-19 vaccine roll-out. In late November, he talked about showing Prime Minister Narendra Modi a third factory at the company’s Pune headquarters which would soon allow the firm to crank out more than 1 billion Covid-19 shots a year.

Yet, as circumstances shifted, so did Poonawalla’s projections in public forums and to the media.

In an interview in November, he said Serum was aiming to have 100 million doses ready in reserve by the end of December, just a quarter of the amount promised by the end of the year. In January, he lowered that even further to 70 million.

Poonawalla in early January said the shortfalls were due to a lack of warehouse space to store the vials after slower than anticipated regulatory approvals in India. The company filed their application for an emergency licence there in early December. Over recent months Poonawalla has also cited US policies for some of his company’s problems, spearheading complaints against a de facto American export ban imposed on some crucial vaccine raw materials.

In January, a fire broke out at one of Serum’s plants. The manufacturer at first downplayed its impact and Poonawalla tweeted that the blaze wouldn’t slow production. But it led to losses of equipment and delays in putting on additional manufacturing lines, curbing expansion, according to a person familiar with the matter who didn’t want to be named discussing internal company business.

“Right now I think they are really, really stuck – that’s a major blow to Covax,” said Cleo Kontoravdi, a member of Imperial College London’s Future Vaccine Manufacturing Research Hub and Vaccine Research Network.

Within the company, there is frustration over how production has been impacted, the person familiar with Serum’s operations said. One of the main reasons pledges weren’t fulfilled was because the global landscape for Covid-19 vaccines kept changing, with shifts in India’s regulations, approvals and other government controls after each target was announced, the person said. The company’s hands were tied by India’s export ban and other government regulations, the person said.

There have been shortages in India as well. Initially, Serum’s supply challenges weren’t apparent there because the immunisation campaign got off to a slow start. Modi’s government was also unclear on how much it would eventually order from Serum, leaving the company with little foresight as to how much capacity was needed.

India’s initial order sheet in January was parsimonious – just 11 million shots at first after Poonawalla attempted to publicly negotiate on pricing with the government. But as the second coronavirus wave swept across the country demand shot up, and supplies started to dwindle.

With its two main suppliers currently stretched, India is relying on a second round of home-grown and imported vaccines to ease that strain. Shots from Biological-E, Cadila Healthcare and Novavax may lead to a near threefold scale-up of the roll-out to 271 million doses a month by October, according to estimates from Investec.



Serum isn’t the only vaccine maker that’s fallen short of its pledges. AstraZeneca was unable to meet promised targets to the European Union because of production issues. The other company supplying India’s roll-out, Bharat Biotech International, has also only provided about 27 million of a promised 1 billion annual doses of its shot. Russia, which only started shipping batches of Sputnik V to India last month, had said it could begin delivering an order of 100 million doses by December last year.


“All of them have over promised and that trend continues,” said Malini Aisola, the New Delhi-based co-convenor of public health watchdog All India Drug Action Network said of the country’s vaccine makers. “The demand is so much greater than what the companies can manufacture.”

https://www.scmp.com/news/asia/south-asia/article/3136585/indias-serum-institute-worlds-biggest-covid-19-vaccine



- - - - - - - - - - 



India’s Serum Institute, the world’s biggest Covid-19 vaccine manufacturer, is at the centre of global shortage


The company has been unable to send any shots overseas since April, when the Indian government banned Covid-19 vaccine exports
Several nations, including Nepal, entered into direct contracts with Serum and are now racing to find new suppliers

The Indian company has been dogged by setbacks, from a ban on exports to a factory fire, that have hampered its ability to fill orders. Photo: ReutersThe Indian company has been dogged by setbacks, from a ban on exports to a factory fire, that have hampered its ability to fill orders. Photo: Reuters
The Indian company has been dogged by setbacks, from a ban on exports to a factory fire, that have hampered its ability to fill orders. Photo: Reute
Around the world, from Bangladesh to Nepal to Rwanda, vulnerable hotspots have been grappling with stalled Covid-19 vaccination programmes as they run out of doses. Many of those shortages can be traced back to a single company: the Serum Institute of India.


The world’s largest vaccine maker, Serum was last year named a top supplier of Covid-19 shots to Covax, the World Health Organization-backed initiative aimed at securing an equitable global roll-out. But the Indian company has been dogged by setbacks, from a ban on exports to a factory fire, that have hampered its ability to fill orders.


Covax has pledged to send shots to some 92 countries, but has so far received only 30 million of the minimum 200 million doses it ordered from Serum, which was to provide the bulk of its early supply. Serum’s travails have now become a key illustration of how the effort to inoculate against Covid-19 has failed the developing world, and a cautionary tale for becoming overreliant on one manufacturer amid a global crisis.


The shortages have occurred as the WHO and public health experts warn that low levels of vaccination in poorer nations could fuel the emergence of dangerous variants and lengthen the global pandemic. Other manufacturers have also had trouble meeting targets or ramping up production of Covid-19 shots, yet Serum’s shortfalls are particularly consequential because Covax and emerging countries were counting on it so heavily.


The company has been unable to send any shots overseas since April, when the Indian government banned Covid-19 vaccine exports amid the country’s
devastating second wave. But some of Serum’s problems began long before.


Last year, Serum’s chief executive officer, Adar Poonawalla, pledged that his vaccine producing colossus would churn out 400 million doses of AstraZeneca’s coronavirus shot for low and middle-income countries by the end of 2020. A month into 2021, he said it had manufactured only 70 million shots because the company had been uncertain about when it would receive a license from India and didn’t have enough warehouse space.
Several nations also entered into direct contracts with Serum and are now racing to find new suppliers. In Nepal – which is struggling with a severe outbreak that’s even reached base camp of Mount Everest – the government says it’s received only half the 2 million shots it ordered directly from Serum, based in the city of Pune in neighbouring India. The rest were supposed to arrive by March.

“We are struggling with the shortage of vaccines,” said Tara Nath Pokhrel, the director of the family welfare division at Nepal’s health ministry.

Nepal, with a population of 28 million, says it’s received only 2.38 million doses: 1 million directly from Serum, another 1 million in grant aid from India, and the rest from Covax. Nepal had been expecting 13 million doses altogether from Covax. But those flows have dried up given Covax was relying heavily on Serum for supply and the Indian company is no longer exporting because of the government restrictions.


The decision to choose Serum as a major Covax supplier “was based, largely, on the company’s massive production capacity, ability to deliver at low cost and the fact that its vaccine was one of the earliest to gain WHO emergency use listing”, said Seth Berkley, chief executive officer at Gavi, the Vaccine Alliance, which has been facilitating Covax and helping fund its orders.
Berkley says Serum’s manufacturing capacity is now expanding, which will help India. Still, Covax and many developing countries are scrambling to find new sources of vaccines after Serum said in recent weeks that exports are unlikely to resume until the end of 2021 given the needs of its overwhelmed homeland.

It’s a void that could potentially be filled by Chinese vaccine makers, with shots from Sinovac Biotech and Sinopharm both recently approved for wider global use by the WHO. Bangladesh stopped giving out first vaccination doses after Serum’s supply shortages and then went on to halt its entire campaign. After the arrival of a limited supply of Chinese vaccines from Sinopharm, the South Asian country resumed inoculations for frontline and emergency workers, but is yet to start a mass vaccination programme.
An Indian man receives a vaccine manufactured by Bharat Biotech in New Delhi. Photo: Reuters
An Indian man receives a vaccine manufactured by Bharat Biotech in New Delhi. Photo: Reuters


The situation Serum now finds itself in is a turnaround from a year ago. Then, its owners – the billionaire Poonawalla family, which founded the firm in 1966 to diversify their business away from racehorse breeding – were thrust into the global spotlight after agreeing to mass produce AstraZeneca’s vaccine, which is called Covishield in India.

Serum had long been a supplier of measles and polio inoculations to the developing world and Adar Poonawalla, who became CEO in 2011, revelled in its position at the centre of the historic Covid-19 vaccine
 roll-out. In late November, he talked about showing Prime Minister Narendra Modi a third factory at the company’s Pune headquarters which would soon allow the firm to crank out more than 1 billion Covid-19 shots a year.

Yet, as circumstances shifted, so did Poonawalla’s projections in public forums and to the media.

In an interview in November, he said Serum was aiming to have 100 million doses ready in reserve by the end of December, just a quarter of the amount promised by the end of the year. In January, he lowered that even further to 70 million.

Poonawalla in early January said the shortfalls were due to a lack of warehouse space to store the vials after slower than anticipated regulatory approvals in India. The company filed their application for an emergency licence there in early December. Over recent months Poonawalla has also cited US policies for some of his company’s problems, spearheading complaints against a de facto American export ban imposed on some crucial vaccine raw materials.


In January, a fire broke out at one of Serum’s plants. The manufacturer at first downplayed its impact and Poonawalla tweeted that the blaze wouldn’t slow production. But it led to losses of equipment and delays in putting on additional manufacturing lines, curbing expansion, according to a person familiar with the matter who didn’t want to be named discussing internal company business.



“Right now I think they are really, really stuck – that’s a major blow to Covax,” said Cleo Kontoravdi, a member of Imperial College London’s Future Vaccine Manufacturing Research Hub and Vaccine Research Network.
Within the company, there is frustration over how production has been impacted, the person familiar with Serum’s operations said. One of the main reasons pledges weren’t fulfilled was because the global landscape for Covid-19 vaccines kept changing, with shifts in India’s regulations, approvals and other government controls after each target was announced, the person said. The company’s hands were tied by India’s export ban and other government regulations, the person said.


There have been shortages in India as well. Initially, Serum’s supply challenges weren’t apparent there because the immunisation campaign got off to a slow start. Modi’s government was also unclear on how much it would eventually order from Serum, leaving the company with little foresight as to how much capacity was needed.
A health worker inoculates a woman with a dose of the Covaxin vaccine in New Delhi. Photo: AFP
A health worker inoculates a woman with a dose of the Covaxin vaccine in New Delhi. Photo: AFP


India’s initial order sheet in January was parsimonious – just 11 million shots at first after Poonawalla attempted to publicly negotiate on pricing with the government. But as the second coronavirus wave swept across the country demand shot up, and supplies started to dwindle.


With its two main suppliers currently stretched, India is relying on a second round of home-grown and imported vaccines to ease that strain. Shots from Biological-E, Cadila Healthcare and Novavax may lead to a near threefold scale-up of the roll-out to 271 million doses a month by October, according to estimates from Investec.

Serum isn’t the only vaccine maker that’s fallen short of its pledges. AstraZeneca was unable to meet promised targets to the European Union because of production issues. The other company supplying India’s roll-out, Bharat Biotech International, has also only provided about 27 million of a promised 1 billion annual doses of its shot. Russia, which only started shipping batches of Sputnik V to India last month, had said it could begin delivering an order of 100 million doses by December last year.


“All of them have over promised and that trend continues,” said Malini Aisola, the New Delhi-based co-convenor of public health watchdog All India Drug Action Network said of the country’s vaccine makers. “The demand is so much greater than what the companies can manufacture.”

https://www.scmp.com/news/asia/south-asia/article/3136585/indias-serum-institute-worlds-biggest-covid-19-vaccine

Friday, 7 May 2021

Novavax to deliver 350 million Covid-19 vaccine doses to Covax scheme

 

NEW YORK (REUTERS) - Novavax's Covid-19 vaccine candidate is yet to be authorised in any country.

Novavax's Covid-19 vaccine candidate is yet to be authorised in any country.PHOTO: REUTERS

 Novavax Inc said on Thursday (May 6) that it has signed an agreement with the Gavi vaccine alliance to manufacture and distribute 350 million doses of its Covid-19 vaccine candidate to countries participating in the Covax facility.

The Covax facility, a global initiative aimed at equitable access to Covid-19 vaccines for poorer countries, is co-led by Gavi, the World Health Organisation and the Coalition for Epidemic Preparedness Innovations.

The company said India's Serum Institute will manufacture and deliver the balance of the 1.1 billion doses of its vaccine to be delivered to the Covax vaccine scheme, under a separate agreement.

While Novavax's vaccine candidate is yet to be authorised in any country, the company and the Serum Institute plan to start delivery of the doses in the third quarter of 2021.

Novavax said it will get an upfront payment from Gavi later this month and an additional payment following an emergency use listing for its vaccine by the World Health Organisation.

Reuters reported earlier this week the company told the European Union it plans to begin delivering its Covid-19 vaccine candidate to the bloc towards the end of this year.